Literature DB >> 12480937

Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons.

Edward B Lee1, Daniel M Skovronsky, Farhad Abtahian, Robert W Doms, Virginia M-Y Lee.   

Abstract

Insoluble pools of the amyloid-beta peptide (Abeta) in brains of Alzheimer's disease patients exhibit considerable N- and C-terminal heterogeneity. Mounting evidence suggests that both C-terminal extensions and N-terminal truncations help precipitate amyloid plaque formation. Although mechanisms underlying the increased generation of C-terminally extended peptides have been extensively studied, relatively little is known about the cellular mechanisms underlying production of N-terminally truncated Abeta. Thus, we used human NT2N neurons to investigate the production of Abeta11-40/42 from amyloid-beta precursor protein (APP) by beta-site APP-cleaving enzyme (BACE). When comparing undifferentiated human embryonal carcinoma NT2- cells and differentiated NT2N neurons, the secretion of sAPP and Abeta correlated with BACE expression. To study the effects of BACE expression on endogenous APP metabolism in human cells, we overexpressed BACE in undifferentiated NT2- cells and NT2N neurons. Whereas NT2N neurons produced both full-length and truncated Abeta as a result of normal processing of endogenous APP, BACE overexpression increased the secretion of Abeta1-40/42 and Abeta11-40/42 in both NT2- cells and NT2N neurons. Furthermore, BACE overexpression resulted in increased intracellular Abeta1-40/42 and Abeta11-40/42. Therefore, we conclude that Abeta11-40/42 is generated prior to deposition in senile plaques and that N-terminally truncated Abeta peptides may contribute to the downstream effects of amyloid accumulation in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12480937     DOI: 10.1074/jbc.M210105200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.

Authors:  David E Hurtado; Laura Molina-Porcel; Jenna C Carroll; Caryn Macdonald; Awo K Aboagye; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

2.  Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.

Authors:  Roxanna Perez-Garmendia; Vanessa Ibarra-Bracamontes; Vitaly Vasilevko; Jose Luna-Muñoz; Raul Mena; Tzipe Govezensky; Gonzalo Acero; Karen Manoutcharian; David H Cribbs; Goar Gevorkian
Journal:  J Neuroimmunol       Date:  2010-09-22       Impact factor: 3.478

3.  Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration.

Authors:  Matthew J Winton; Edward B Lee; Eveline Sun; Margaret M Wong; Susan Leight; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2011-05-25       Impact factor: 6.167

4.  Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation.

Authors:  Zhuohao He; Jing L Guo; Jennifer D McBride; Sneha Narasimhan; Hyesung Kim; Lakshmi Changolkar; Bin Zhang; Ronald J Gathagan; Cuiyong Yue; Christopher Dengler; Anna Stieber; Magdalena Nitla; Douglas A Coulter; Ted Abel; Kurt R Brunden; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Med       Date:  2017-12-04       Impact factor: 53.440

5.  Proteomic identification of sorting nexin 6 as a negative regulator of BACE1-mediated APP processing.

Authors:  Hirokazu Okada; Wenzhu Zhang; Corrinne Peterhoff; Jeremy C Hwang; Ralph A Nixon; Sung H Ryu; Tae-Wan Kim
Journal:  FASEB J       Date:  2010-03-30       Impact factor: 5.191

6.  Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology.

Authors:  Roy Hamilton; Sunil Patel; Edward B Lee; Eric M Jackson; Joanna Lopinto; Steven E Arnold; Christopher M Clark; Anuj Basil; Leslie M Shaw; Sharon X Xie; M Sean Grady; John Q Trojanowski
Journal:  Ann Neurol       Date:  2010-10       Impact factor: 10.422

7.  Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia.

Authors:  David J Irwin; Corey T McMillan; Sharon X Xie; Katya Rascovsky; Vivianna M Van Deerlin; H Branch Coslett; Roy Hamilton; Geoffrey K Aguirre; Edward B Lee; Virginia M Y Lee; John Q Trojanowski; Murray Grossman
Journal:  Brain       Date:  2018-01-01       Impact factor: 13.501

8.  Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease.

Authors:  Syaun Sung; Hengxuan Yang; Kunihiro Uryu; Edward B Lee; Lei Zhao; Diana Shineman; John Q Trojanowski; Virginia M-Y Lee; Domenico Praticò
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Diabetes and Alzheimer's disease - is there a connection?

Authors:  Anders A F Sima; Zhen-Guo Li
Journal:  Rev Diabet Stud       Date:  2007-02-10

10.  Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.

Authors:  Oliver Wirths; Henning Breyhan; Holger Cynis; Stephan Schilling; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2009-06-23       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.